New pill takes aim at tough lung cancer mutations

NCT ID NCT06043817

Recruiting now Disease control Sponsor: Pierre Fabre Medicament Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests an experimental oral drug called STX-721 in people with advanced non-small cell lung cancer that has specific EGFR or HER2 gene mutations. The trial has three parts: first finding a safe dose, then confirming the best dose, and finally expanding to more participants to see how well the drug shrinks tumors. About 345 people will take part across multiple sites.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: STX-721 (also called PFL-721), an oral drug
What this could lead to: If it works, this could offer a new targeted treatment option for people with a hard-to-treat form of lung cancer that has specific genetic mutations.
What could go wrong: This is an early first-in-human study, so safety and effectiveness are not yet known. The drug may not shrink tumors or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EGFR/HER2 EXON 20 INSERTION MUTATION NON-SMALL CELL LUNG CANCER NSCLC

Contacts and locations

Locations

CHA Bundang Medical Center, CHA University
RECRUITING

Seongnam-si, 13496, South Korea
Charité - Universitätsmedizin Berlin (CBF) - Hindenburgdamm 30
RECRUITING

Berlin, 12203, Germany
Chungbuk National University Hospital
RECRUITING

Cheongju-si, 28644, South Korea
City of Hope
RECRUITING

Duarte, California, 91010, United States
City of Hope
RECRUITING

Huntington Beach, California, 92648, United States
City of Hope
RECRUITING

Irvine, California, 92618, United States
EDOG Institut de Cancerologie de l'Ouest - PPDS
RECRUITING

Saint-Herblain, Loire-Atlantique, 44115, France
Gustave Roussy
RECRUITING

Villejuif, 94800, France
Hospital Regional Universitario de Malaga - Hospital General
RECRUITING

Málaga, Malaga, 29010, Spain
Hospital Universitario Ramon y Cajal
RECRUITING

Madrid, 28034, Spain
Hospital Universitario Virgen del Rocio
RECRUITING

Seville, 41013, Spain
Institut Claudius Regaud - PPDS
RECRUITING

Toulouse, 31059, France
Instituto de Investigacion Oncologica Vall dHebron (VHIO) - EPON
RECRUITING

Barcelona, 8035, Spain
Levine Cancer Institute - Charlotte
RECRUITING

Charlotte, North Carolina, 28204-2990, United States
NEXT Virginia
RECRUITING

Fairfax, Virginia, 22031-2171, United States
National Taiwan University Hospital
RECRUITING

Taipei, 10002, Taiwan
Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis
RECRUITING

Amsterdam, 1066, Netherlands
SCRI Oncology Partners - PPDS
RECRUITING

Nashville, Tennessee, 37203, United States
Seoul National University Hospital
RECRUITING

Seoul, 03080, South Korea
Taipei Veterans General Hospital
RECRUITING

Taipei, 11217, Taiwan
Thomas Jefferson University Research Facility
RECRUITING

Philadelphia, Pennsylvania, 19107, United States
University of Texas MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030-4009, United States
University of Utah - Huntsman Cancer Institute - PPDS
RECRUITING

Salt Lake City, Utah, 84112-5550, United States
Universitätsklinikum Carl Gustav Carus an der TU Dresden
RECRUITING

Dresden, 01307, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.